Upcoming Live CE Webinar- Drug Information Update

The Division of Drug Information (DDI)- serving the public by providing information on human drug products and drug product regulation by FDA

LIVE HEALTHCARE PROFESSIONAL DDI WEBINAR SERIES

FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is presenting a series of continuing educationwebinars targeting the needs of all healthcare professionals and future clinicians

 “DDI Webinar Series: Understanding Abuse Deterrent Opioids”

Will be held on:

December 8, 2016

Time:  1:00 pm to 2:00 pm (EST) 

To register for the online meeting, please visit: https://collaboration.fda.gov/ddi120816/event/registration.html

After registering, you will receive a calendar invitation with details on how to join the online meeting.

Activity Outline

Description: This series of educational webinars are designed to aid Healthcare Professionals, Pharmacy, Nurse Practitioner, Physician Assistant and Medical students to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety. This webinar will discuss the various properties of abuse-deterrent opioids, how the FDA evaluates and determines labeling for abuse-deterrent properties, and the real-world impact these formulations have on healthcare providers.

Series Objectives:

• Explain how to utilize FDA’s drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes.
• Describe and inform health care providers of recent labeling changes which would impact prescribing and medication management to optimize patient care. 

References:

• Webster L,  St Marie B,  McCarberg B,  Passik SD,  Panchal SJ,  Voth E., Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain. Journal of Opioid Management [2011, 7(3):235-245]
• Paul M. Coplan, Hrishikesh Kale, Lauren Sandstrom, Craig Landau, Howard D. Chilcoat , Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics; Pharmacoepidemiology and Drug Safety, Volume 22, Issue 12, December 2013  Pages 1274–1282 : http://onlinelibrary.wiley.com/doi/10.1002/pds.3522/full
• Effect of Abuse-Deterrent Formulation of OxyContin, N Engl J Med 2012; 367:187-189 July 12, 2012: http://www.nejm.org/doi/full/10.1056/nejmc1204141#t=article
• Abuse-Deterrent Opioids: What You Need to Know, featuring Douglas Throckmorton, MD: http://www.medscape.com/viewarticle/867679
• MedWatch - http://www.fda.gov/Safety/MedWatch/
• Regulations  - 21 CFR 314.80 Post-marketing reporting of adverse drug experiences at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.80
• FDA website: Potential Signals of Serious Risks/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS) at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.80
• FDA website: Post-market Drug and Biologic Safety Evaluations at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ucm204091.htm
• Report to the FDA Commissioner from the Task Force on Risk Management May 1999: Managing the Risks from Medical Product Use: Creating a Risk Management Framework Part 3: How Does FDA Conduct Post-marketing Surveillance And Risk Assessment? http://www.fda.gov/Safety/SafetyofSpecificProducts/ucm180549.htm
• FDA’s response to IOM 2006 Report on The Future of Drug Safety – Promoting and Protecting the Health of the Public (2007) http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM171627.pdf
• FDA report to Congress – Changing the Future of Drug Safety: FDA Initiatives to Strengthen and Transform the Drug Safety System, July 2009 http://www.fda.gov/downloads/Safety/SafetyofSpecificProducts/UCM184046.pdf
• ISMP(Institute for Safe Medication Practices) website – FDA Safety Alerts at http://www.ismp.org/Tools/FDASafetyAlerts.asp
• ISMP QuarterWatch – Monitoring FDA MedWatch reports at http://www.ismp.org/quarterwatch/default.aspx
• National Patient Safety Foundation: Improving Root Cause Analyses and Actions to Prevent Harm at  http://www.npsf.org/?page=RCA2
• Farley DO et al; Adverse Event Reporting Practices by U.S. Hospitals: Results of a National Survey. Quality and Safety in Health Care 2008; 17:416-423.
• Joint Commission http://www.jointcommission.org
• AHRQ (Agency for Healthcare research and Quality), Patient Safety Network (PSNet): Voluntary Patient Safety Event Reporting (Incident Reporting), August 2014 https://psnet.ahrq.gov/primers/primer/13. 

Session Learning Objectives: After completion of this activity, the participant will be able to:

1. Identify and differentiate abuse-deterrent properties
2. Describe the role of abuse-deterrent opioids in the epidemic
3. List the types of studies involved in abuse-deterrent opioids 
4. Summarize the impact of abuse-deterrent opioids may have on health care providers

Target Audience: This activity is intended for physicians, nurses, pharmacists, and pharmacy technicians.

Schedule:

1:00-2:00 pm –  “DDI Webinar Series: Understanding Abuse Deterrent Opioids”  presented by John Whyte MD, MPH

Continuing Education:The Food and Drug Administration, Center for Drug Evaluation and Research is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians and physician assistants.    

The Food and Drug Administration – Center for Drug Evaluation and Research designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)^TM.  Physicians and physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

The FDA-Center for Drug Evaluation and Research is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. (ACPE Universal Activity No. 0601-0000-16-119-L04-P and ACPE Universal Activity No. 0601-0000-16-120-L04-T).  This program meets the criteria for 1 contact hour(s) of pharmacy education and pharmacy technician education. 

 

This activity is a knowledge-based activity. These CE activities are primarily constructed to transmit knowledge (i.e., facts). The facts must be based on evidence as accepted in the literature by the health care professions.

FDA, Center for Drug Evaluation and Research is an approved provider of continuing nursing education by the Maryland Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

This 1 contact hour Education Activity is provided by FDA, Center for Drug Evaluation and Research.  Each nurse should claim only the time that he/she actually spent in the educational activity.

Requirements for receiving CE Credit:Physicians, nurses, pharmacists, and pharmacy technicians, and those claiming non-physician CME:  attendance is verified by Adobe Connect login or by a sign-in sheet, and completion of the final activity evaluation.  Final activity evaluations must be completed within two weeks after the activity.

Pharmacists and Pharmacy Technician participants:  partial credit cannot be awarded therefore you must attend the entire activity to receive CPE credit. No exceptions.  Pharmacists and Pharmacy Technicians will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.

Statements of Credit:Physicians and Nurses Statements of Credit for CE will be issued 10 weeks after the last session of this activity.  Pharmacists and Pharmacy Technicians should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit. 

Disclosure:

Faculty:

-        John Whyte, MD, MPH, Medical Director PASE, FDA/CDER/OCD/PASES-nothing to disclose

Planning Committee:

-        Kara Burke, PharmD, Consumer Safety Officer, FDA/CDER/OCOMM/DDI-nothing to disclose

-        Kimberly DeFronzo, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI-nothing to disclose

-        Virginia Giroux, MSN, ARNP, CE Program Administrator, FDA/CDER/OEP/DLOD-nothing to disclose

-        Lesley Navin, RN, MSN, Consumer Safety Officer, FDA/CDER/OCOMM/DDI-nothing to disclose

-        Edward Weinstein, MD, Medical Officer, Office of New Drugs, Division of Anti-Infective Products-nothing to disclose

CE Consultation and Accreditation Team:

-        Justin Gorinson, CHES, ORISE Fellow, FDA/CDER/OEP/DLOD-nothing to disclose

-        Karen Zawalick, CE Consultation and Accreditation Team Leader, FDA/CDER/DLOD-nothing to disclose

Registration Fees and Refunds: Registration is complimentary therefore refunds are not applicable.

Requirements for Certificate of Completion (Non CE):Must attend 80% of the lectures (verified by a sign-in sheet).

Initial Release Date: December 8, 2016

--------------

Please direct your comments or questions via email to DDIWebinars@fda.hhs.gov.

FUTURE WEBINAR DATES:Please visit www.fda.gov/DDIWebinars for future webinar dates and information.